Week 1 HW: Biomanufacturing Concept

1. What you would like to biomanufacture and why?

Target Product: A commercial-grade, purified cell-free plasmid DNA amplification toolkit based on the ColE1 origin of replication (a “ColE1-Ciro” kit).

Motivation: The goal is utilitarian: to create a GMP-compliant, highly scalable alternative to bacterial fermentation for manufacturing therapeutic DNA. Current plasmid production for mRNA vaccines and viral vectors requires massive bioreactors and extensive downstream purification to remove toxic bacterial endotoxins (LPS) and genomic DNA. By shifting from a crude lysate to a completely defined mixture of purified proteins, we can manufacture endotoxin-free, pharmaceutical-grade circular DNA in a benchtop tube, drastically lowering the barrier to entry for gene therapy manufacturing.

2. What living system would you use?

Chassis: A highly defined, reconstituted in vitro replication system composed entirely of purified recombinant E. coli enzymes (no living cells or crude lysate).

High-Level Process:

  • Inputs: A target ColE1 plasmid, a chemically defined buffer (dNTPs, NTPs, magnesium, ATP), and a cocktail of roughly nine highly purified enzymes.
  • Biological Process: Instead of relying on a messy cellular background, we tightly control the biochemistry. Purified RNA Polymerase transcribes the RNA II primer. Purified RNase H cleaves it. Purified DNA Pol I initiates the strand. Then, the purified DNA Pol III holoenzyme and DnaB helicase take over for rapid elongation, protected by Single-Stranded Binding protein (SSB). Finally, purified DNA Gyrase and Topoisomerase IV relieve topological strain and separate the daughter plasmids.
  • Outputs: Pure, supercoiled, closed-circular plasmid DNA with zero background host genomic DNA or endotoxins.

3. How would you use automation?

I would use a programmable desktop liquid-handling robot (such as an Opentrons OT-2 or Cambrian Orca) to perform combinatorial stoichiometric optimization. Unlike living cells that self-regulate enzyme levels, a purified system requires the engineer to define the exact molar ratio of all 9+ proteins. If you have too much Pol I relative to Pol III, replication will be hopelessly slow; if you have too little Topoisomerase, the DNA will tangle and crash. The liquid handler will array thousands of micro-reactions across 384-well plates, systematically varying enzyme concentrations, ATP levels, and magnesium to empirically discover the optimal commercial formulation.

4. How much would you need to make, and how long would it take?

(a) How much? A meaningful scale is producing enough pharmaceutical-grade plasmid DNA to act as the template for a pilot batch of mRNA vaccines (e.g., roughly 10,000 doses). A standard mRNA in vitro transcription (IVT) reaction typically requires about 10 micrograms of plasmid DNA per milligram of mRNA produced. To produce enough mRNA for 10,000 doses, we need approximately 100 mg of highly pure circular plasmid DNA.

(b) How long?

  • Volume Assumption: Highly optimized purified replication systems can achieve yields of around 3 mg/mL because no cellular resources are wasted on maintaining life. To produce 100 mg of DNA, we only need a total reaction volume of roughly 33 mL.
  • Rate Assumption: The purified DNA Pol III holoenzyme retains its blazing in vivo speed of ~500 bases per second.
  • Time Estimate: In an automated, temperature-controlled 33 mL bioreactor running at 30°C, the purified replication cycle is incredibly efficient. Without the competing nucleases found in crude extracts, the reaction will reach substrate saturation in 2 to 4 hours. Downstream purification is nearly instantaneous (just a simple buffer exchange or DNA precipitation), meaning the entire batch is ready in under a day.

5. What don’t you know yet?

  1. Protein Stability and Shelf-Life: Can we manufacture and co-package all 9+ multi-subunit proteins in a single master mix that remains stable on a shelf or at -20°C for months without losing specific activity?
  2. The RNA I Accumulation Crash: In vivo, the ColE1 inhibitor RNA I is constantly degraded by host RNases. In our purified system, RNA I will rapidly accumulate and potentially halt replication. We must experimentally determine if we need to add a purified RNase to the mix to actively destroy RNA I, or if we must mandate that users mutate the RNA I promoter on their template plasmids.
  3. Topological Limits: Without the background “helper” proteins present in a whole cell, will our purified Gyrase and Topo IV concentrations be sufficient to manage the immense supercoiling generated by larger plasmids (e.g., >15 kb), or will the replication fork stall under the physical tension?